Raymond James Reviews Gilead Pipelines, Takes Bullish Stance On Pharma Stock

A rundown of each segment Gilead addresses paints a bullish picture for the stock, Seedhouse said in the initiation note. The HCV business, which should start showing signs of stability in the bottom half of 2018 and generate around $2.5 billion in revenue in a few years, Seedhouse said.

from Yahoo Finance https://ift.tt/2lKdXDn